- Lexaria Bioscience is a company that is passionate about establishing alternatives to inhalation for rapid-response drug substance delivery in order to eliminate the lung harm that smoking or vaping may cause
- Lexaria’s DehydraTECH platform has generated numerous patents with more pending as a way to provide quick substance delivery to the user’s bloodstream and better access through the blood-brain barrier
- Lexaria recently announced it had further improved DehydraTECH, as demonstrated in testing that showed early pilot-stage human trial participants began to note edible THC effects in under 10 minutes – more rapidly than the previous DehydraTECH formulation
- Prior technology testing has focused on animal subjects and non-psychoactive products
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is announcing further advances in its proprietary oral drug delivery platform DehydraTECH™, which is innovating edible consumption of nicotine and cannabis products as a quick-response alternative to inhalation.
Lexaria’s early pilot-stage human trials with tetrahydrocannabinol (THC) delivery show its newest formulation of DehydraTECH-enhanced edibles begin providing cannabinoid effectiveness in less than 10 minutes, which is about twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations, according to a company news release (http://cnw.fm/2owxO).
Lexaria has been developing DehydraTECH solutions as alternatives to smoked or vaped drug delivery over the course of the past three years, establishing a means whereby edible consumption of certain substances can provide results at rates comparable to inhaled substances and faster than ingested substances in general.
In June, the company announced that a series of animal studies showed its DehydraTECH solution could improve on cannabidiol (CBD) delivery to the blood system by 811 percent and to brain tissue by 1,937 percent when compared with generic medium-chain triglyceride (MCT) formulations.
The latest announcement marks a new milestone in that the studies involved humans instead of animals and utilized THC instead of CBD, demonstrating further potential applications of DehydraTECH technology.
Speed of onset in the use of various drug products is regarded as a key metric of the products’ potential value, particularly where pain-relief and the relief of other physical torments are concerned. For example, nicotine is recognized as a highly addictive substance that can provoke then alleviate physical withdrawal symptoms or cravings, while certain cannabis extracts have been promoted in recent years as significant remedies for pain and muscle spasms or seizure disorders.
Inhalation has traditionally shown the greatest benefit in terms of rapid-response drug delivery benefits, but Lexaria has been passionate about delivering alternatives because of the harm substance inhalation can do to users’ lungs, as demonstrated by the history of smoking tobacco products and recent concerns about deaths and illnesses linked to vaping cannabis or nicotine products, which in turn have led health insurers to penalize customers who smoke or vape products (http://cnw.fm/7mHhX).
Because of DehydraTECH’s rapid-response capabilities, Lexaria’s technology virtually eliminates a key reason people might risk sustained injury to their lungs in using tobacco and cannabis products. Lexaria’s tech works as a complimentary product with other companies’ research and development on cannabinoids, providing Lexaria a niche as a potential collaborative team member rather than a competitor as other industry developments occur.
Lexaria’s position is further strengthened by its worldwide patents and pending patents for oral or ingestible non-psychoactive cannabinoids – it has been awarded 16 patents in the United States and Australia and is awaiting completion of the process for 60 additional patents in other countries (http://cnw.fm/3uWv8).
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CanadianCannabisWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor
CanadianCannabisWire is part of the InvestorBrandNetwork.